Management Guidelines for Children with Idiopathic Generalized Epilepsy
Authors:
Open Access
- 18 November 2005
- Vol. 46 (s9) , 112-116
Abstract
Summary: Most idiopathic generalized epilepsy (IGE) begins in childhood. Clinicians face many important management decisions for these children; however the existing literature provides little scientific guidance. Time of Diagnosis: At the time of presentation, it is unclear how accurately IGE seizures and syndromes are diagnosed and how consistent are the EEG correlates. Investigations beyond EEG are of uncertain value but probably are not needed. Selection of an initial antiepileptic drug (AED) is not based on any adequately powered, blinded, randomized comparative trials; however, reasonable evidence supports the use of valproic acid (VPA), lamotrigine and ethosuccimide as initial treatment for childhood absence epilepsy (CAE). Many large case series suggest the value of VPA for juvenile myoclonic epilepsy (JME) but the relative value of other, newer AEDs has not been established. First years of treatment: Once AED treatment is started, it is difficult to establish that absence seizures are completely controlled and the importance of interictal spike‐wave discharge remains uncertain. The value of restrictions on the child's activities has not been well studied; however serious accidents appear to be a justifiable concern in children with uncontrolled absence. Assessing the risk from photosensitivity in JME is challenging. Length of treatment: The optimal length of treatment for IGE is unclear. There is a high rate of remission in CAE when AEDs are discontinued after 1–2 years of seizure freedom; however, long‐term remission in CAE occurs in only 65%. It is usually assumed that treatment for JME is life long, although about 10% appear to have permanent remission in adolescence. Discontinuing AED treatment in JME requires a very individual risk assessment. Preparation for adult life: Long‐term social outcome for children with CAE is often unsatisfactory even if the epilepsy remits. The reasons are unclear and successful interventions have not been described. Long‐term social outcome for JME has not been adequately described. Conclusions: Further research is needed to justify the direction of many of the necessary management decisions in the diagnosis and treatment of IGE syndromes.Keywords
This publication has 34 references indexed in Scilit:
- Lamotrigine versus Valproic Acid as First‐line Monotherapy in Newly Diagnosed Typical Absence Seizures: An Open‐label, Randomized, Parallel‐group StudyEpilepsia, 2004
- Childhood Epilepsy: What Is the Evidence for What We Think and What We Do?Journal of Child Neurology, 2003
- Restrictions for Children with Epilepsy Commission of Pediatrics of the ILAEEpilepsia, 1997
- Gabapentin in Naive Childhood Absence Epilepsy: Results From Two Double-Blind, Placebo-Controlled, Multicenter StudiesJournal of Child Neurology, 1996
- Will a Critical Level of Hyperventilation‐Induced Hypocapnia Always Induce an Absence Seizure?Epilepsia, 1996
- Absence EpilepsiesEpilepsia, 1995
- Juvenile Myoclonic Epilepsy: A 5‐Year Prospective StudyEpilepsia, 1994
- The utility of ambulatory EEG monitoring in typical absence seizuresBrain and Development, 1991
- Interobserver Variability in the ILAE Classification of Seizures in ChildhoodEpilepsia, 1988
- Comparative Study of Ethosuximide and Sodium Valproate in the Treatment of Typical Absence Seizures (Petit Mal)Developmental Medicine & Child Neurology, 1982